Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes
Status:
Not yet recruiting
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
The aim of this proposed study is to evaluate the efficacy and safety of hydroxychloroquine
(HCQ) in children's interstitial lung diseases(chILD) with genetic causes. This study is a
randomized controlled clinical trial.